Bayer and MSD want to tap into the same market of HFrEF patients with vericiguat, a first-in-class soluble guanylate cyclase (sGC) stimulator. Now the companies are ready for a big push into phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback